常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.71/-6.72
|
|
企業價值
5.55M
|
| 資產負債 |
|
每股賬面淨值
1.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform. |

5.6 
